June 7, 2012
Novartis Pharma announced on June 5 that it has revised the domestic package insert for the hypertension treatment Rasilez 150 mg Tablet (aliskiren) to include a contraindication against its combined use with ACE inhibitors or ARBs in patients with diabetes...read more